PT - JOURNAL ARTICLE AU - Vishala Mishra AU - Joseph P. Dexter TI - Response of Unvaccinated US Adults to Official Information About the Pause in Use of the Johnson & Johnson-Janssen COVID-19 Vaccine AID - 10.1101/2021.06.08.21258558 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.08.21258558 4099 - http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258558.short 4100 - http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258558.full AB - On April 13, 2021 the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) recommended in a pause in use of the Johnson & Johnson (J&J)-Janssen COVID-19 vaccine due to reports of cerebral venous sinus thrombosis (CVST) in recently vaccinated individuals. The announcement of the pause required development of a coordinated communication strategy under extreme time pressure and careful messaging by stakeholders to mitigate reduced public confidence in COVID-19 vaccines, as was observed following the temporary suspension of the Oxford-AstraZeneca vaccine in many countries. In this survey study, we evaluated understanding and impressions of the CDC’s public online information about the J&J-Janssen pause among unvaccinated US adults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a CoronaVirusFacts Alliance Grant from the Poynter Institute, a Neukom Fellowship, and a Harvard Data Science Fellowship. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Harvard University's Committee on the Use of Human Subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is available from the corresponding author on request.